comparemela.com

Latest Breaking News On - Brussels stock exchange bios - Page 1 : comparemela.com

BioSenic raises €500,000 in private placement of new shares

PRESS RELEASE – REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED.

France generalMont saint guibertWaals gewestSouth africaMichelle boxallGhislaine gasparettoBanque delubac cieGestys santSeitosei actifinBelgian code on companiesBiosenic groupInternational media enquiriesIb communicationsEuronext brusselsEuronext parisBelgian code

BioSenic S A : Information on the total number of voting

Information on the total number of voting rights and shares Mont-Saint-Guibert, Belgium, September 1, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and.

Mont saint guibertWaals gewestFrance generalSeitosei actifinNeil hunter michelle boxallGhislaine gasparettoNeither the companyInternational media enquiriesIb communicationsEuronext brusselsGraft versus host diseaseLouvain la neuve science parkMesenchymal stromal cellsChief executiveMedia enquiriesFrench investor enquiries

BioSenic puts Phase IIb ALLOB trial on hold

INSIDE INFORMATION Prior efficacy unmatched but excellent safety profile confirmed, timing of ALLOB administration for optimal bone repair to.

Mont saint guibertWaals gewestFrance generalLieven huysseNeil hunter michelle boxallGhislaine gasparettoInternational media enquiriesIb communicationsEuronext brusselsChief medical officerHost diseaseFull study populationPer protocolChief executive officerArsenic trioxideSystemic sclerosis

BioSenic and Pluristyx sign term sheet for market

INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cells BioSenic to potentially receive royalty.

France generalMont saint guibertWaals gewestAnnie florence loyerBert bouserieNeil hunter michelle boxallSeitosei actifinGhislaine gasparettoMahendra raoBiosenic pluristyxInternational media enquiriesIb communicationsCell bankEuronext brusselsMesenchymal stem cellsBone therapeutics

BioSenic appoints Yves Sagot as Independent Director

REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company.

Mont saint guibertWaals gewestFrance generalMerck seronoSeitosei actifinAnnie florence loyerGhislaine gasparettoYves sagotBert bouserieTerry sadlerYves sadlerNeil hunter michelle boxallIb communicationsManagement of technologyCancer centerInternational media enquiries

vimarsana © 2020. All Rights Reserved.